This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Brand Names
- Gardasil, Gardasil 9
- Generic Name
- Human papillomavirus type 11 L1 capsid protein antigen
- DrugBank Accession Number
- DB10300
- Background
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- L1 protein, Human papillomavirus type 11 Vaccine
- Recombinant human papillomavirus type 11 L1 protein
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Human papillomavirus (hpv) infection •••••••••••• •••••••••• •••••••••• Prevention of Infection caused by human papillomavirus type 11 •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image GARDASIL Human papillomavirus type 11 L1 capsid protein antigen (40 µg) + Human papillomavirus type 16 L1 capsid protein antigen (40 µg) + Human papillomavirus type 18 L1 capsid protein antigen (20 µg) + Human papillomavirus type 6 L1 capsid protein antigen (20 µg) Injection, suspension Intramuscular; Parenteral Merck Sharp & Dohme B.V. 2014-07-08 Not applicable Italy 
Gardasil Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) Injection, suspension Intramuscular Merck Sharp & Dohme B.V. 2021-03-18 Not applicable EU 
Gardasil Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL) Injection, suspension Intramuscular Remedy Repack 2014-02-13 2015-02-11 US 
GARDASIL Human papillomavirus type 11 L1 capsid protein antigen (40 µg) + Human papillomavirus type 16 L1 capsid protein antigen (40 µg) + Human papillomavirus type 18 L1 capsid protein antigen (20 µg) + Human papillomavirus type 6 L1 capsid protein antigen (20 µg) Injection, suspension Intramuscular; Parenteral Merck Sharp & Dohme B.V. 2014-07-08 2022-05-19 Italy Gardasil Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) Injection, suspension Intramuscular Merck Sharp & Dohme B.V. 2021-03-18 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z845VHQ61P
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Active Not Recruiting Not Available Cervical Cancer / Human Papillomavirus (HPV) Infections / Vaginal Cancers / Vulvar Cancer / Warts, Genital 1 somestatus stop reason just information to hide Not Available Completed Not Available Evaluating Attitudes Toward HPV Vaccinations in Pharmacies / Evaluating the Provision of HPV Vaccines in a Pharmacy 1 somestatus stop reason just information to hide Not Available Completed Not Available Healthy Volunteers (HV) 1 somestatus stop reason just information to hide Not Available Completed Not Available Human Immunodeficiency Virus Type 1 (HIV-1) Infection / Human Papilloma Virus (HPV) 1 somestatus stop reason just information to hide Not Available Completed Basic Science Sexually Transmitted Diseases, Viral 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular Suspension Intramuscular Suspension Parenteral Injection, suspension Intramuscular; Parenteral Injection, solution Intramuscular Injection, suspension Intramuscular 40 mcg Solution Intramuscular Injection Injection, suspension - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at February 13, 2021 10:52